Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Oct 24, 2026

Gt Biopharma, Inc. (GTBP)

A forensic read on Gt Biopharma, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

F · Poor — capital at risk

Forensic grade

Distress

Financial health

-292.1

Distress distance

Clean

Earnings quality

Forensic signals

-1377.4%

ROE

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Gt Biopharma, Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -292.1, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+102.3%/yr

FY2023–FY2025

Share-count dilution. Diluted share count changed +309% over the last 2 years to FY2025 (+102.3%/yr). The count is growing — 1.3M shares in FY2023, 5.5M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~102.3% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~76%.

OCF ($13M)

FY2025

Shareholder returns. Returned $229,000 to shareholders (buybacks + dividends) in FY2025, while operating cash flow itself was ($13M) — zero or negative. Capex isn't disclosed for FY2025, but free cash flow can't have been positive when operating cash flow already isn't, so the entire return is coming from debt or cash reserves, not cash the business generated.

Key fundamentals

Return on Equity-1377.4%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Gt Biopharma, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Oct 24, 2026. Forensic signals flag probability, not certainty.